PureTech Health PLC
LSE:PRTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PureTech Health PLC
Long-Term Investments
PureTech Health PLC
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PureTech Health PLC
LSE:PRTC
|
Long-Term Investments
$200.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
114%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Investments
$268m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Investments
$3B
|
CAGR 3-Years
34%
|
CAGR 5-Years
43%
|
CAGR 10-Years
-13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Investments
$5.7B
|
CAGR 3-Years
287%
|
CAGR 5-Years
207%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Investments
$10.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
32%
|
|
PureTech Health PLC
Glance View
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.
See Also
What is PureTech Health PLC's Long-Term Investments?
Long-Term Investments
200.2m
USD
Based on the financial report for Dec 31, 2024, PureTech Health PLC's Long-Term Investments amounts to 200.2m USD.
What is PureTech Health PLC's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
114%
Over the last year, the Long-Term Investments growth was -39%. The average annual Long-Term Investments growth rates for PureTech Health PLC have been -20% over the past three years , -23% over the past five years , and 114% over the past ten years .
